EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Autores de IDIVAL

• 

  Ignacio Durán Martínez

  Autor

  ignaciojose.duran@scsalud.es

Autores ajenos al IDIVAL

• Rosenberg JE
• Powles T
• Sonpavde GP
• Loriot Y
• Lee JL
• Matsubara N
• Vulsteke C
• Castellano D
• Mamtani R
• Wu C
• Matsangou M
• Campbell M
• Petrylak DP

Abstract

Introduction: This exploratory analysis evaluated efficacy and safety data for enfortumab vedotin versus chemotherapy over a median follow-up of <^>-2 years from EV-301. Materials and methods: Patients with locally advanced/metastatic urothelial carcinoma with prior platinum-containing chemotherapy and disease progression during/after programmed cell death protein 1/ligand 1 inhibitor treatment were randomized to enfortumab vedotin or chemotherapy (docetaxel, paclitaxel, vinflunine). Endpoints were overall survival (primary), progression-free survival (PFS), objective response, and safety. Results: In total, 608 patients were included (enfortumab vedotin, n = 301; chemotherapy, n = 307). With a median follow-up of 23.75 months, 444 deaths had occurred (enfortumab vedotin, n = 207; chemotherapy, n = 237). Risk of death was reduced by 30% with enfortumab vedotin versus chemotherapy [hazard ratio (HR) 0.70 (95% confidence interval [CI] 0.58-0.85); one-sided, log-rank P = 0.00015]; PFS improved with enfortumab vedotin [HR 0.63 (95% CI 0.53-0.76); one-sided, log-rank P < 0.00001]. Treatment-related adverse event rates were 93.9% for enfortumab vedotin and 91.8% for chemotherapy; grade > 3 event rates were 52.4% and 50.5%, respectively. Grade > 3 treatment-related decreased neutrophil count (14.1% versus 6.1%), decreased white blood cell count (7.2% versus 1.4%), and anemia (7.9% versus 2.7%) were more common with chemotherapy versus enfortumab vedotin; maculopapular rash (7.4% versus 0%), fatigue (6.8% versus 4.5%), and peripheral sensory neuropathy (5.1% versus 2.1%) were more common with enfortumab vedotin. Of special interest adverse events, treatment-related skin reactions occurred in 47.3% of patients receiving enfortumab vedotin and 15.8% of patients receiving chemotherapy; peripheral neuropathy occurred in 48.0% versus 31.6%, respectively, and hyperglycemia in 6.8% versus 0.3%. Conclusions: After a median follow-up of <^>-2 years, enfortumab vedotin maintained clinically meaningful overall response benefit remained consistent. Adverse events were manageable; no new safety signals were observed.

Copyright © 2023. Published by Elsevier Ltd.

Keywords

• antibody–drug conjugate; long-term survival follow-up; urinary bladder neoplasms